Antidiabetic combination therapy

This page covers all Antidiabetic combination therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting AMPK (metformin); Insulin receptor (insulin), PPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component).

Targets

AMPK (metformin); Insulin receptor (insulin) · PPAR-γ (thiazolidinedione component); mitochondrial respiratory chain complex I (biguanide component)

Marketed (1)

• Metformin + Insulin · University of Virginia · Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while insulin directly lowers blood glucose by promoting cellular glucose uptake and utilization.

Phase 3 pipeline (2)

• Biguanides, thiazolidinediones · University of Pittsburgh · Diabetes
  This combination of biguanides and thiazolidinediones improves insulin sensitivity and reduces hepatic glucose production through complementary mechanisms in type 2 diabetes management.
• Metformin + Intermittent Insulin Therapy · Mount Sinai Hospital, Canada · Diabetes
  Metformin reduces hepatic glucose production and improves insulin sensitivity, while intermittent insulin therapy provides periodic exogenous insulin to maintain glycemic control.